Correlation of SOX9 and NM23 genes with the incidence and prognosis of prostate cancer Retraction in /10.3892/ol.2024.14324

Xi,Ming; Wan,Song; Hua,Wei; Zhou,Yulin; Jiang,Wencong; Hu,Jianxin

doi:10.3892/ol.2018.9828

Correlation of SOX9 and NM23 genes with the incidence and prognosis of prostate cancer

Retraction in: /10.3892/ol.2024.14324

Authors:
- Ming Xi
- Song Wan
- Wei Hua
- Yulin Zhou
- Wencong Jiang
- Jianxin Hu
View Affiliations

Affiliations: Department of Urology, Huadu District People's Hospital, Southern Medical University, Guangzhou, Guangdong 510530, P.R. China, Department of Urology, Guizhou Provincial People's Hospital, Guiyang, Guizhou 550002, P.R. China
Published online on: December 12, 2018 https://doi.org/10.3892/ol.2018.9828
Pages: 2296-2302
Copyright: © Xi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Correlation of sex determining region Y‑box (SOX)9 and NM23 genes with the incidence and prognosis of prostate cancer (PC) was investigated. SOX9‑small interfering ribonucleic acid (siRNA) and NM23‑siRNA were constructed and transfected into PC‑3 cells. The expression levels of SOX9 and NM23 messenger RNAs (mRNAs) and proteins in PC‑3 cells were detected via reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) and western blotting. MTT assay was adopted to examine the proliferation ability of the transfected cells, and Transwell assay was applied to detect the migration ability of the transfected cells. Sixty‑three patients with PC and 56 patients with benign prostatic hyperplasia who were treated in Huadu District People's Hospital were enrolled. Correlation analyses were conducted for the relative expression levels of SOX9 and NM23 and the Gleason grade; and the survival curves of the patient SOX9/NM23 (S/N) Cq values were plotted. The proliferation and migration abilities of PC‑3 cells were remarkably reduced after low expression of SOX9 (P<0.01), while those of PC‑3 cells were significantly improved after low expression of NM23 (P<0.01). Compared with that in tissues of PC patients, the relative expression of SOX9 mRNA in patients with benign prostatic hyperplasia was obviously decreased (P<0.01), while that of NM23 mRNA was significantly elevated (P<0.01). The larger the S/N was, the shorter the patient's survival time would be (P<0.05). The low expression of SOX9 gene can significantly reduce the proliferation and migration abilities of PC cells, which is negatively associated with the incidence and prognosis of patients. The low expression of NM23 gene can markedly enhance the proliferation and migration abilities of PC cells, and it is positively related to the incidence and prognosis of patients.

View Figures

View References

1	Fang M, Nakazawa M, Antonarakis ES and Li C: Efficacy of abiraterone and enzalutamide in pre- and postdocetaxel castration-resistant prostate cancer: A trial-level meta-analysis. Prostate Cancer. 2017:85608272017. View Article : Google Scholar : PubMed/NCBI
2	Katreddy RR, Bollu LR, Su F, Xian N, Srivastava S, Thomas R, Dai Y and Wu B: Correction: Do psychological harms result from being labelled with an unexpected diagnosis of abdominal aortic aneurysm or prostate cancer through screening? A systematic review. BMJ Open. 8:e017565corr12018. View Article : Google Scholar : PubMed/NCBI
3	McClinch K, Avelar RA, Callejas D, Izadmehr S, Wiredja D, Perl A, Sangodkar J, Kastrinsky DB, Schlatzer D and Cooper M: Small molecule activators of protein phosphatase 2A for the treatment of castration-resistant prostate cancer. Cancer Res. 22:48–63. 2018.
4	Song XL, Huang B, Zhou BW, Wang C, Liao ZW, Yu Y and Zhao SC: miR-1301-3p promotes prostate cancer stem cell expansion by targeting SFRP1 and GSK3β. Biomed Pharmacother. 3:2185–2195. 2018.
5	Ma F, Ye H, He HH, Gerrin SJ, Chen S, Tanenbaum BA, Cai C, Sowalsky AG, He L, Wang H, et al: SOX9 drives WNT pathway activation in prostate cancer. J Clin Invest. 126:1745–1758. 2016. View Article : Google Scholar : PubMed/NCBI
6	Xie Y, Lu W, Liu S, Yang Q, Carver BS, Li E, Wang Y, Fazli L, Gleave M and Chen Z: Crosstalk between nuclear MET and SOX9/β-catenin correlates with castration-resistant prostate cancer. Mol Endocrinol. 28:1629–1639. 2014. View Article : Google Scholar : PubMed/NCBI
7	Qin GQ, He HC, Han ZD, Liang YX, Yang SB, Huang YQ, Zhou L, Fu H, Li JX, Jiang FN, et al: Combined overexpression of HIVEP3 and SOX9 predicts unfavorable biochemical recurrence-free survival in patients with prostate cancer. Onco Targets Ther. 7:137–146. 2014.PubMed/NCBI
8	Wang G, Lunardi A, Zhang J, Chen Z, Ala U, Webster KA, Tay Y, Gonzalez-Billalabeitia E, Egia A, Shaffer DR, et al: Zbtb7a suppresses prostate cancer through repression of a Sox9-dependent pathway for cellular senescence bypass and tumor invasion. Nat Genet. 45:739–746. 2013. View Article : Google Scholar : PubMed/NCBI
9	Carotenuto M, de Antonellis P, Chiarolla CM, Attanasio C, Damiani V, Boffa I, Aiese N, Pedone E, Accordi B, Basso G, et al: A therapeutic approach to treat prostate cancer by targeting Nm23-H1/h-Prune interaction. Naunyn Schmiedebergs Arch Pharmacol. 388:257–269. 2015. View Article : Google Scholar : PubMed/NCBI
10	Andolfo I, De Martino D, Liguori L, Petrosino G, Troncone G, Tata N, Galasso A, Roma C, Chiancone F, Zarrilli S, et al: Correlation of NM23-H1 cytoplasmic expression with metastatic stage in human prostate cancer tissue. Naunyn Schmiedebergs Arch Pharmacol. 384:489–498. 2011. View Article : Google Scholar : PubMed/NCBI
11	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real time quantitative PCR and the 2(Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
12	Cancian M and Renzulli JF II: Nonmetastatic castration-resistant prostate cancer: A modern perspective. Urology. 116:13–16. 2018. View Article : Google Scholar : PubMed/NCBI
13	Alabed YZ: Prostate cancer lytic bone metastases imaged with 18F-fluorocholine PET/CT. Clin Nucl Med. 43:220–221. 2018. View Article : Google Scholar : PubMed/NCBI
14	Kabir A, Zendehdel R and Tayefeh-Rahimian R: Dioxin exposure in the manufacture of pesticide production as a risk factor for death from prostate cancer: A meta-analysis. Iran J Public Health. 47:148–155. 2018.PubMed/NCBI
15	Alexis O and Worsley A: An integrative review exploring black men of African and Caribbean backgrounds, their fears of prostate cancer and their attitudes towards screening. Health Educ Res. 1:325–339. 2018.
16	Wan YP, Xi M, He HC, Wan S, Hua W, Zen ZC, Liu YL, Zhou YL, Mo RJ, Zhuo YJ, et al: Expression and clinical significance of SOX9 in renal cell carcinoma, bladder cancer and penile cancer. Oncol Res Treat. 40:15–20. 2017. View Article : Google Scholar : PubMed/NCBI
17	Song W, Kwon GY, Kim JH, Lim JE, Jeon HG, Il Seo S, Jeon SS, Choi HY, Jeong BC and Lee HM: Immunohistochemical staining of ERG and SOX9 as potential biomarkers of docetaxel response in patients with metastatic castration-resistant prostate cancer. Oncotarget. 7:83735–83743. 2016. View Article : Google Scholar : PubMed/NCBI
18	Su ZH and Li JC: Genetic instability of gene nm23H1 in colon cancer of Chinese patient. Shi Yan Sheng Wu Xue Bao. 36:325–329. 2003.(In Chinese). PubMed/NCBI
19	Esposito S, Russo MV, Airoldi I, Tupone MG, Sorrentino C, Barbarito G, Di Meo S and Di Carlo E: SNAI2/Slug gene is silenced in prostate cancer and regulates neuroendocrine differentiation, metastasis-suppressor and pluripotency gene expression. Oncotarget. 6:17121–17134. 2015. View Article : Google Scholar : PubMed/NCBI
20	Huang CS, Shih MK, Chuang CH and Hu ML: Lycopene inhibits cell migration and invasion and upregulates Nm23-H1 in a highly invasive hepatocarcinoma, SK-Hep-1 cells. J Nutr. 135:2119–2123. 2005. View Article : Google Scholar : PubMed/NCBI
21	Kim YI, Park S, Jeoung DI and Lee H: Point mutations affecting the oligomeric structure of Nm23-H1 abrogates its inhibitory activity on colonization and invasion of prostate cancer cells. Biochem Biophys Res Commun. 307:281–289. 2003. View Article : Google Scholar : PubMed/NCBI